

Name of Journal: *World Journal of Diabetes*

ESPS Manuscript NO: 24407

Manuscript Type: Clinical Trials Study

Prediction of the Effect on Antihyperglycaemic Action of Sitagliptin by
Plasma Active Form GLP-1

Akifumi Kushiya*, Takako Kikuchi, Kentaro Tanaka, Tazu Tahara,
Toshiko Takao, Yukiko Onishi, Yoko Yoshida, Shoji Kawazu, Yasuhiko
Iwamoto

Match Overview

1	CrossCheck 101 words Aso, Y.. "Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DP	3%
2	Internet 26 words crawled on 19-Sep-2015 www.researchgate.net	1%
3	CrossCheck 23 words Kentaro Tanaka. "Risk of macrovascular disease stratified by stage of chronic kidney disease in type 2 diabetic	1%
4	Internet 22 words crawled on 17-May-2011 www.ncbi.nlm.nih.gov	1%
5	CrossCheck 20 words Kim, Bo-Hyung, Sung Eun Kim, Dongwoo Kang, Kyoung Soo Lim, Jung-Ryul Kim, In-Jin Jang, Sang-Goo Shin, S	1%
6	CrossCheck 15 words Tremblay, André J., Benoît Lamarche, Carolyn F. Deacon, S. John Weisnagel, and Patrick Couture. "Effects of sit	<1%

学术搜索

找到约 915 条结果 (用时0.10秒)

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

时间不限

2016以来

2015以来

2012以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

☒ 包括专利☒ 包含引用

Effect of single oral doses of **sitagliptin**, a dipeptidyl peptidase-4 inhibitor, on incretin and **plasma** **glucose levels** after an oral glucose tolerance test in patients with ... [endocrine.org](#) 中

GA Herman, A Bergman, C Stevens... - The Journal of ..., 2006 - [press.endocrine.org](#)

... EC 50 was calculated and represents the **plasma** concentration required to achieve 50% of the maximal **effect**. The **predicted plasma** concentration where 75% of the maximal **effect** would be observed (EC 75) was also estimated to represent near-maximal **effects**. ...

被引用次数: 410 相关文章 所有 7 个版本 引用

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [novonordisk.com](#)

[DJ Drucker](#), MA Nauck - The Lancet, 2006 - Elsevier

... Notably, **effects** on glucagon secretion, like those on insulin secretory responses, are glucose-dependent, whereas counter-regulatory ... does intravenous glucose (even if leading to the same glycaemic increments), this incretin **effect** is substantially ... **Antidiabetic actions** of GLP- ...

被引用次数: 2324 相关文章 所有 15 个版本 引用

Pharmacokinetics and pharmacodynamic **effects** of the oral DPP - 4 inhibitor **sitagliptin** in middle - aged obese subjects

GA Herman, A Bergman, F Liu... - The Journal of ..., 2006 - Wiley Online Library

... This study characterized the pharmacokinetics and pharmacodynamic **effects** of chronic (28 days) dosing with **sitagliptin** ... The dose of 200 mg bid was chosen because it was **predicted** to be ... In this study, **sitagliptin** treatment had no significant **effect** on total **GLP-1** levels versus ...

被引用次数: 177 相关文章 所有 4 个版本 引用

Dipeptidyl peptidase - 4 inhibitors administered in combination with metformin result in an additive [nature.com](#) 中的 increase in the **plasma** concentration of **active GLP - 1**

EM Migoya, [R Bergeron](#), JL Miller... - Clinical ..., 2010 - Wiley Online Library

... population worldwide in the year 2000; the prevalence of this disease is **predicted** to increase to ... Metformin administered as a single agent did not **affect** postprandial DPP-4 **activity** relative

Article types[Clinical Trial](#)[Review](#)[Customize ...](#)**Text availability**[Abstract](#)[Free full text](#)[Full text](#)**PubMed**[Commons](#)[Reader comments](#)[Trending articles](#)**Publication
dates**[5 years](#)[10 years](#)[Custom range...](#) No items found.

[全部](#)[图片](#)[新闻](#)[视频](#)[更多 ▾](#)[搜索工具](#)

找到约 19,900 条结果 (用时 0.70 秒)

显示的是以下查询字词的结果: **Prediction of the effect on *antihyperglycemic* action of sitagliptin by plasma active form glucagon-like peptide-1**

仍然搜索: **Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1**

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl ...

press.endocrine.org/doi/pdf/10.1210/jc.2006-1009 - 翻译此页

作者: GA Herman - 2006 - 被引用次数: 414 - 相关文章

2006年8月23日 - Peptidase-4 Inhibitor, on Incretin and **Plasma** Glucose. Levels after an ... of oral **antihyperglycemic** agents in development for the treatment of ... tivity over 24 h, enhanced **active GLP-1** and GIP levels, increased **Sitagliptin Effects** on Incretin and Glucose in Diabetes ... The **predicted plasma** concentra-

Full Text - Endocrine Society

press.endocrine.org/doi/full/10.1210/jc.2006-1009 - 翻译此页

作者: GA Herman - 2006 - 被引用次数: 414 - 相关文章

DPP-4 inhibitors are a novel class of oral **antihyperglycemic** agents in ... Results: **Sitagliptin** dose-dependently inhibited **plasma** DPP-4 **activity** over 24 h, ... **Active GLP-1** and GIP stimulate glucose-dependent insulin biosynthesis and release, The **predicted plasma** concentration where 75% of the maximal **effect** would be ...

Very Short-Term Effects of the Dipeptidyl Peptidase-4 ... - N...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ 翻译此页

作者: K Murai - 2014 - 被引用次数: 2 - 相关文章

2014年11月25日 - AUC_{0-2h} and AUC_{0-4h} for postprandial **plasma** glucagon also